Tim Andrews, 67, is still alive and is back on the waiting list for a human donor. However, the success of his highly experimental procedure means more patients are scheduled to get genetically modified animal organs.
A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.
Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.
PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations.
Although these tools have proven themselves valuable in numerous settings, they must be used with caution, especially by patients and nonradiologist providers who may be seeking clarification on imaging reports.
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.
![An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.](/sites/default/files/styles/240x220/public/2024-04/screen_shot_2024-04-26_at_10.55.10_am.png.webp?itok=ZMT_brpB)
